Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

Short-duration trastuzumab did not show noninferiority to long-duration trastuzumab overall. Certain patients with low/intermediate HER2-positive disease may benefit from a shorter, 9-week course.

Among the 261 patients in the trastuzumab deruxtecan group and the 263 in the trastuzumab emtansine group, the median ages were 54 years and most were from Asia (57.1% and 60.8%, respectively ...

Under the assumption that the median DFS time would be 15 months, it was hypothesized that the addition of trastuzumab on NRG-RTOG 1010 would result in a hazard ratio of 0·60, corresponding to a ...

Read full article: Naked pedestrian killed in hit-and-run in Washtenaw County Baby peregrine falcons being banded in Macomb County. Get ready for some fabulous deals for when you're on the go ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...

There is a commercial access agreement for trastuzumab emtansine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

CHICAGO (October 3, 2017): Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for ...

Adding trastuzumab to chemotherapy led to a 37% relative improvement in OS (hazard ratio [HR], 0.63; 95% CI, 0.54 to 0.73; P < .001) and an increase in 10-year OS rate from 75.2% to 84%. These results ...